CD117: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
==Positive== | ==Positive== | ||
*[[Gastrointestinal stromal tumour]]. | *[[Gastrointestinal stromal tumour]]. | ||
*[[Seminoma]]. | *[[Seminoma]].<ref name=pmid24832161>{{cite journal |author=Ulbright TM, Tickoo SK, Berney DM, Srigley JR |title=Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=e50–9 |year=2014 |month=August |pmid=24832161 |doi=10.1097/PAS.0000000000000233 |url=}}</ref> | ||
*[[Renal oncocytoma]]. | *[[Renal oncocytoma]]. | ||
*[[Chromophobe renal cell carcinoma]]. | *[[Chromophobe renal cell carcinoma]]. | ||
Revision as of 22:18, 1 August 2016
CD117 is common immunostain.
Positive
- Gastrointestinal stromal tumour.
- Seminoma.[1]
- Renal oncocytoma.
- Chromophobe renal cell carcinoma.
- Renal hybrid oncocytic/chromophobe tumour.
- Adenoid cystic carcinoma.
See also
References
- ↑ Ulbright TM, Tickoo SK, Berney DM, Srigley JR (August 2014). "Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the international society of urological pathology consensus conference". Am. J. Surg. Pathol. 38 (8): e50–9. doi:10.1097/PAS.0000000000000233. PMID 24832161.